|
Job Description
Job Description
Postdoctoral position is available in the laboratory of Prof. Jolanta Grembecka, University of Michigan, Ann Arbor, to develop small molecule inhibitors for targeted therapies in cancer. We are seeking for highly motivated synthetic organic chemists and medicinal chemists to join a comprehensive drug discovery program. Dr. Grembecka’s lab. is conducting highly interdisciplinary research focused on pre-clinical development of novel anti-cancer drugs, which covers medicinal chemistry, structural biology, biochemical and biophysical assays, biological and animal studies. The successful candidate will be involved in designing and synthesis of small molecule inhibitors targeting proteins as potential anti-cancer agents with a major focus on synthesis of heterocyclic compounds targeting protein-protein interactions relevant to cancer. The duties will include design and synthesis of new analogues of existing leads to develop biologically active compounds for testing in cancer cells and animals. The candidate must be independent in designing synthetic routes, solving challenging synthetic problems, efficient in synthesizing targeted molecules, including multi-step synthesis.
Requirements
Applicant must have PhD in synthetic organic chemistry or medicinal chemistry and be a first author on at least 3 publications. This position requires extensive experience in designing synthetic routes for new classes of compounds, solving challenging synthetic problems, SAR analysis. Applicant needs an expertise in using HPLC, NMR and MS for organic chemistry applications. Excellent oral and written communication skills in English are required.
How to apply
Please submit cover letter, CV, and contact information for 2-3 references combined into one PDF file by e-mail to: jolantag@umich.edu.
Contact: Jolanta Grembecka, PhD, Assistant Professor
Department of Pathology, University of Michigan
Ann Arbor, MI, 48109, USA
https://www.pathology.med.umich.edu/index.php?t=page&id=1473
e-mail: jolantag@umich.edu
Relevant publications:
1. Borkin, D. et al., Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo, Cancer Cell, 2015, March 25, [Epub ahead of print]. http://www.cell.com/cancer-cell/abstract/S1535-6108%2815%2900066-5.
2. S. He, et al, High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein-Protein Interaction., J. Med. Chem., 2014, 57 (4):1543-56. .
3. Grembecka J, et al., Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 2012, 8 (3):277-84. |
|
med.umich.edu
